UK-1745
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure.
For research use only. We do not sell to patients.
- CAS No.: 170684-14-7
- Formula: C16H23ClN2O2
- Molecular Weight:310.82
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Adrenergic Receptor Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 170684-14-7
-
Molecular Weight 310.82
-
Formula C16H23ClN2O2
-
SMILES
CC1(C2=C(NC1=O)C(C)=CC3=C2O[C@](CN)(C)[C@H]3C)C.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Sawada, et al. "Pharmacological Characterization of Effects of UK-1745, a Novel Cardiotonic Agent withβ-Adrenoceptor-blocking Action, in Aequorin-loaded Canine Right Ventricular Muscle." Journal of molecular and cellular cardiology 31.5 (1999): 1047-1062. [Content Brief]
[2]. Uchida, et al. "Cardiovascular effects of (2RS, 3SR)-2-aminomethyl-2, 3, 7, 8-tetrahydro-2, 3, 5, 8, 8-pentamethyl-6H-furo-[2, 3-e] indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties." Arzneimittel-forschung 48.3 (1998): 219-231. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
UK-1745 Related Classifications
HY-117181 Related Classifications
Powered by Bioz